According to the phase 2 SWOG S1605 monotherapy study conducted with 74 CIS patients treated with atezolizumab (anti-PD-L1 agent), CR rates reached 41.1% at three months and 26.0% at six months [59]. The gene discussed is CD274; the disease is in situ carcinoma.